Scope and claim analysis for U.S. Patent 12,168,022 (MAC lung infection; aerosolized liposomal amikacin once daily for ≥84 days)
United States Patent No. 12,168,022 claims a specific inhaled therapeutic regimen for Mycobacterium avium complex (MAC) lung infection using aerosolized liposomal amikacin with defined lipid chemistry, dose ranges, dosing schedule, treatment duration, and microbiological endpoint timing. The claim set is anchored by independent claim 1 (method of treatment with multiple structural and functional constraints), with dependent claims narrowing the salt form, phospholipid identity, lipid concentration, fill volume, patient population, prior-treatment unresponsiveness, add-on concomitant drugs, and clinical outcomes.
What is the core protected method in U.S. Patent 12,168,022?
Short answer: The patent protects a method for treating MAC lung infection by delivering about 560–590 mg amikacin (or salt) encapsulated in liposomes composed of electrically neutral phospholipid + cholesterol, administered by nebulization to the lungs once daily for at least 84 days, achieving ≥3 consecutive negative MAC sputum cultures, where the MAC sputum cultures are measured 28 days after initiating treatment.
Independent claim 1: claim “center of gravity”
Claim 1 is drafted as a multi-constraint infringement gate. A practicing accused method must satisfy all key limitations:
-
Disease and patient
- Treating MAC lung infection in a patient “in need thereof.”
-
Drug substance and dose
- Administering a pharmaceutical composition comprising about 560 mg to about 590 mg of amikacin (or a pharmaceutically acceptable salt).
- Dependent claims explicitly name amikacin sulfate as one option.
-
Formulation architecture
- The amikacin is encapsulated in a plurality of liposomes.
- Liposome lipid component consists of:
- electrically neutral phospholipid, and
- cholesterol.
- No other lipid components are permitted in the “consists of” limitation (subject to doctrine-of-equivalents arguments).
-
Delivery modality and aerosol composition
- Administration comprises aerosolizing the pharmaceutical composition via a nebulizer.
- The aerosolized product contains:
- free amikacin (or salt) and
- liposomal complexed amikacin (or salt).
-
Dosing regimen
- Once daily.
- Single dosing session per day.
-
Treatment duration
- Administration period at least 84 days.
- Dependent claims expand to longer fixed durations (including 6–18 months and 18 months).
-
Microbiology outcome
- Treating comprises achieving at least three consecutive negative MAC sputum cultures.
- Timing structure: MAC sputum cultures are measured 28 days after initiating treatment during the administration period.
How the “28-day measurement” limitation functions
Claim 1 ties the microbiological sampling to a specific time anchor: cultures are measured 28 days after initiating treatment “during the administration period.” This does two things for enforcement:
- It pressures accused regimens to match the timepoint at which negative cultures are assessed.
- It can narrow infringement where a generic or biosimilar-equivalent product yields negatives only at later or different intervals, even if the final achieved “three consecutive negatives” occurs.
How do dependent claims narrow scope (salt, lipid identity, concentrations, device volume)?
What salt forms are explicitly covered?
- Claim 2: amikacin salt = amikacin sulfate.
The independent claim already covers “amide or salt” broadly (“about 560–590 mg of amikacin, or an equivalent dose of a pharmaceutically acceptable salt”). Claim 2 closes in on a concrete salt form for fallback coverage.
Which phospholipids are explicitly covered?
- Claim 3: electrically neutral phospholipid = electrically neutral phosphatidylcholine.
- Claim 4: specifically DPPC (dapalmitoylphosphatidylcholine).
This means the patent’s broader “electrically neutral phosphatidylcholine” corridor can be enforced even if DPPC is swapped, but the strongest fallback is DPPC.
What lipid concentration ranges are claimed?
- Claim 5: composition comprises:
- about 30 mg/mL to about 40 mg/mL DPPC, and
- about 10 mg/mL to about 20 mg/mL cholesterol.
This is a numeric guardrail. A product with the same “DPPC + cholesterol only” lipid set but outside these concentration windows may avoid that dependent claim while still potentially infringing the independent claim depending on how strictly lipid “consists of” is interpreted in the formulation specifics.
What fill volume is claimed?
- Claim 6: pharmaceutical composition is about 8.4 mL.
This is a dosing-form factor limitation. If an accused method uses a different per-session fill volume while maintaining total amikacin dose, it may avoid claim 6.
What patient subpopulations and prior-treatment conditions expand claim coverage?
Underlying lung disease limitation
- Claim 7: patient has a non-cystic fibrosis underlying lung disease.
This narrows to the common MAC bronchiectasis/non-CF phenotype. It can matter if someone targets CF-MAC or other CF populations.
Prior unresponsiveness to guideline-based therapy (GBT)
- Claim 8: patient previously unresponsive to ATS/IDSA MAC guideline-based therapy (GBT).
This is a claim narrowing device that can matter for evidence in litigation (treatment history). It also aligns to real-world payer and clinical trial framing for MAC.
Concomitant therapy add-on coverage
-
Claim 9: patient is administered one or more additional therapeutics.
-
Claim 10: add-on can include:
- macrolide antibiotic,
- rifamycin compound,
- quinolone,
- aminoglycoside,
- ethambutol,
- isoniazid,
- cefoxitin,
- imipenem,
- or combinations.
-
Claims 11–13: enumerates representative drug choices:
- Macrolides (claim 11): azithromycin, clarithromycin, erythromycin, and many others listed.
- Rifamycins (claim 12): rifampin, rifabutin, rifapentine, rifaximin.
- Aminoglycosides (claim 13): extensive list including gentamicin, tobramycin, plazomicin, etc.
This drafting supports infringement arguments against clinicians who follow a multi-drug MAC regimen while inserting the patented aerosolized liposomal amikacin as one component.
What formulation variants are included (aqueous dispersion)?
- Claim 14: pharmaceutical composition is an aqueous dispersion.
This can protect a particular dosage form class (common for liposomes) and may help distinguish from non-aqueous delivery systems.
How do longer treatment durations change infringement exposure?
Claim 1 requires at least 84 days. Dependent claims map additional duration options:
- Claim 15: administration period at least:
- 3 months, 4 months, 5 months, 6 months, 12 months, or 18 months.
- Claim 16: administration period is at least 6 months.
- Claim 20: administration period is 18 months.
- Claims 28–30: combinations including negative-sputum sustained + 18 months + specific outcome endpoints.
Longer-duration claims give the patent leverage against regimens used in chronic MAC management where therapy often extends beyond 12 months.
How specific is the sputum culture endpoint?
Timing and “consecutive negative cultures”
- Claim 1: at least three consecutive negative MAC sputum cultures.
- Claim 17: “time to achieve the first negative MAC sputum culture” is about:
- Claim 18: specifically about 28 days.
- Claim 19: negative culture is sustained during or after administration period.
These are layered claims that can be asserted based on different evidence structures:
- If the accused regimen reaches first negativity at ~28 days and then achieves three consecutive negatives, claims 17 and 18 plus claim 1 are strong.
- If the first negative occurs later, claim 17 still might be triggered depending on the day ranges proven.
- If sustained negativity is documented beyond the end of therapy, claim 19 further tightens.
What functional clinical endpoints are claimed (FEV1, oxygen saturation, 6MWT)?
Claim 1 is a method tied to microbiological outcomes; dependent claims add respiratory performance endpoints.
- Claim 21: increased FEV1 for at least 15 days after the administration period ends, compared to pre-treatment.
- Claim 22: improved blood oxygen saturation for at least 15 days after end of treatment.
- Claim 23: increased distance in 6-minute walk test (6MWT) compared to pre-treatment.
- Claims 30: repeats 6MWT with other chained limitations.
These endpoints create additional hooks for proof and can support enforcement even if some disputes arise about sputum culture cadence, though ultimately claim 1’s microbiology elements remain the independent anchor for a “method of treating” claim.
How strong is the patent estate logic within this single patent?
This patent is engineered as an “inhaled product + regimen” combination claim set. The strongest aspects are:
- Route + device-agnostic delivery mechanism: “aerosolizing via a nebulizer” is central. Many alternative MAC inhalation technologies (e.g., dry powder, catheter-based) may avoid that limitation.
- Lipid composition “consists of”: the limitation that liposome lipid components consist of electrically neutral phospholipid and cholesterol can restrict formulation variations.
- Dose range: about 560–590 mg amikacin anchors dosing, reducing plausible design-around by shifting total dose.
- Schedule and duration: once daily, and at least 84 days, with specific fallback to 18 months.
- Microbiology timing: three consecutive negative cultures and the 28-day measurement anchor can narrow infringement even where outcomes are clinically similar.
The weaker aspects, from an infringement-breadth standpoint, are mostly practical:
- It is harder to show infringement if an accused regimen uses a substantially different dose schedule, nebulizer methodology, lipid concentrations, or sputum measurement timeline.
- Numeric ranges in dependent claims (DPPC, cholesterol, fill volume) create additional avoidance pathways if an accused product stays within independent-claim lipid architecture but shifts dependent parameters.
What design-arounds are most plausible given the claim structure?
The claims are so tight that design-around typically requires modifying at least one of the core limitation clusters:
-
Change encapsulation architecture
- Use non-liposomal amikacin, or liposomes with lipids beyond “electrically neutral phospholipid + cholesterol” (to break “consists of”).
-
Change delivery modality
- Replace nebulization with a different inhalation device/format not meeting “via a nebulizer.”
-
Change dosing schedule
- Avoid “once daily in a single dosing session” (e.g., twice daily or multi-session dosing).
-
Change dose amount
- Move outside “about 560–590 mg” total amikacin per treatment session/regimen as framed.
-
Change duration
- Treat for less than the relevant minimum duration (but chronic MAC treatment makes this hard commercially).
-
Shift sampling/endpoint alignment
- A regimen that achieves negativity but does not match “measured 28 days after initiating treatment” and “three consecutive negatives” may avoid specific dependent assertions, though claim 1 still requires those functional outcomes.
What is missing for a full patent landscape and scope map?
No usable bibliographic or legal-status data (publication number, assignees, filing dates, prosecution history, continuations, related family members, PTAB events, court cases, or Orange Book/ANDA/BLA linking) is provided here. Without that, a complete “patent landscape” across the family and across competitor assets cannot be produced without risking factual inaccuracies.
Key Takeaways
- U.S. Patent 12,168,022 protects a specific MAC lung infection treatment regimen using aerosolized liposomal amikacin.
- The independent claim 1 requires: (i) defined amikacin dose range (about 560–590 mg), (ii) liposomes made only of electrically neutral phospholipid + cholesterol, (iii) nebulized once-daily administration, (iv) ≥84 days therapy, and (v) ≥3 consecutive negative MAC sputum cultures, with cultures measured 28 days after initiating treatment.
- Dependent claims add enforceable fallbacks on: amikacin sulfate, DPPC + cholesterol concentration windows, ~8.4 mL dosage volume, non-CF patient subset, ATS/IDSA GBT unresponsive history, concomitant drug classes, aqueous dispersion, extended durations including 18 months, and post-therapy respiratory functional endpoints (FEV1, oxygen saturation, 6MWT).
FAQs
1) What must an accused regimen show to infringe claim 1 of U.S. 12,168,022?
It must use the claimed inhaled liposomal amikacin formulation (lipid “consists of” neutral phospholipid + cholesterol; aerosolized by nebulizer; aerosol contains both free and liposomal complexed amikacin), with the claimed dose range, once-daily schedule, ≥84-day duration, and the microbiology endpoint structure (≥3 consecutive negative MAC sputum cultures with the cultures measured at the 28-day timepoint).
2) Can infringement occur if the phospholipid is not DPPC?
Claim 4 is DPPC-specific, but claim 3 covers electrically neutral phosphatidylcholine more broadly. A regimen could avoid DPPC-dependent claims while still potentially meeting the independent architecture if the phospholipid qualifies under claim 3 and other claim 1 limitations are met.
3) Does the patent require three consecutive negative sputum cultures during treatment or after?
Claim 1 requires at least three consecutive negative MAC sputum cultures during the relevant administration period construct, with a defined measurement anchor at 28 days after initiating treatment. Claim 19 adds “sustained during or after” for its dependent hook.
4) Are combination MAC regimens covered?
Yes. Claims 9–13 explicitly include patients receiving additional therapeutics, listing macrolides, rifamycins, quinolones, aminoglycosides, ethambutol, and other agents.
5) What changes are most likely to avoid the strongest dependent claims?
Moving out of the dependent numeric ranges for DPPC and cholesterol, changing the fill volume away from ~8.4 mL, altering dosing away from once daily single-session, or using delivery/formulation that breaks the “liposomes of only neutral phospholipid + cholesterol” constraint.
References (APA)
- United States Patent 12,168,022. (Patent claims provided in prompt text).
